v3.25.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Cash flows from operating activities    
Net loss $ (57,225) $ (65,760)
Adjustments to reconcile net loss to net cash used in operations:    
Depreciation and amortization 4,347 5,246
Gain on disposal of fixed assets (22)
Impairment of intangible assets 3,027
Impairment of operating lease right-of-use assets 406
Unrealized gain on derivative liability (3,853)
Unrealized gain on warrant liability (2,238)
Loss on debt extinguishment 4,654
Inventory write-downs 127
Non-cash interest expense 7,325
Amortization of debt discount and issuance costs on notes payable 9,915
Share-based compensation expense 2,248 9,522
Net accretion of premium on short-term investments (284) (776)
Change in:    
Accounts receivable 886 717
Inventory (5,798) (723)
Other current and non-current assets (2,170) 606
Accounts payable 207 (784)
Accrued liabilities 1,087 (2,747)
Contract liabilities and other current liabilities 32 109
Operating lease liabilities (2,188) (1,944)
Other long-term liabilities (260) (488)
Net cash used in operating activities (43,315) (53,484)
Cash flows from investing activities    
Sales of investment securities 26,688 28,311
Purchases of investment securities (32,878) (25,570)
Purchases of property and equipment (435) (271)
Cash paid for Ibeo business combination (6,300)
Net cash used in investing activities (6,625) (3,830)
Cash flows from financing activities    
Principal payments under finance leases (10)
Principal payments under notes payable (5,500)
Proceeds from stock option exercises 62
Net proceeds from issuance of common stock and warrants 73,268 26,093
Net cash provided by financing activities 67,758 26,155
Effect of exchange rate changes on cash, cash equivalents, and restricted cash 469 133
Change in cash, cash equivalents, and restricted cash 18,287 (31,026)
Cash, cash equivalents, and restricted cash at beginning of period 56,247 49,391
Cash, cash equivalents, and restricted cash at end of period 74,534 18,365
Supplemental schedule of non-cash investing and financing activities    
Common stock issued in conversions of notes payable 21,980
Issuance of warrants 6,297
Acquisition of right-of-use asset 139
Foreign currency translation adjustment 665 101
Unrealized (loss) gain on investment securities, available-for-sale $ (14) $ 33

Source

HTML PDF
ZIP